FINWIRES · TerminalLIVE
FINWIRES

調査速報:CFRAはGenerac Holdings Inc.の株式に対する「ホールド」評価を維持。

By

-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。Generacは、第1四半期に好調な業績を発表しました。売上高は前年同期比12%増の10億6,000万ドルとなり、特にデータセンター需要の加速に牽引された商業・産業部門の28%増が大きかったことが要因です。一方、住宅部門の売上高は、家庭用非常用発電機の価格上昇が販売量の減少によって相殺されたため、わずか1%増にとどまりました。調整後EBITDAマージンは15.9%から18.3%へと大幅に拡大しました。これは、商業・産業部門の販売量増加による高い営業レバレッジと、再編された住宅部門事業における大幅なコスト削減を反映したものです。当社は、商業・産業部門の力強い成長と受注残高の拡大を、当社のポジティブな投資判断を支える重要な要因と見ています。経営陣は、第1四半期の好業績と急速に拡大する商業・産業部門の受注残高を背景に、通期業績見通しを引き上げました。 12ヶ月目標株価を235ドルから275ドルに引き上げ、2027年のEPS見通し10.70ドル(従来10.42ドル)の25.7倍と評価します。これはGNRCの5年先予想PER平均に近い水準ですが、収益変動性を考慮すると電気機器業界の同業他社よりは低い水準です。また、2026年のEPS予想も8.10ドルから8.56ドルに引き上げます。

Related Articles

Research

Research Alert: CFRA Retains Buy Rating On Shares Of Vertex Pharmaceuticals Incorporated

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After Q1 results, we lower our target price to $535 from $579, 24.4x our 2027 EPS, a discount to VRTX's 10-year historical forward P/E average. We maintain our 2026 EPS view of $19.40 and our 2027 EPS estimate at $21.92. VRTX's Q1 2026 was marked by robust revenue growth, successful commercial execution of new products, and significant progress in its clinical pipeline, particularly in the renal space. The company's CF franchise remains the primary revenue driver, while new products like Casgevy and Gernavics are beginning to contribute meaningfully to growth, accounting for approximately 25% of the total product revenue growth in Q1. Pipeline advancement remains robust, in our view, with the completion of the rolling BLA submission for povetacicept in IgA nephropathy representing a significant regulatory milestone. Using a Priority Review Voucher, VRTX expects an expedited six-month FDA review timeline, which is encouraging.

$VRTX
Asia

ALS Flags Unauthorized Access to Its IT Systems

ALS (ASX:ALQ) reported a cyber incident involving unauthorized third-party access to some of its information technology (IT) systems, temporarily disrupting parts of its operations, according to a Tuesday Australian bourse filing.The company, with support from external cybersecurity specialists, has implemented containment measures in line with incident response procedures, restoring most operations while continuing targeted remediation in affected areas, per the filing.The company has informed the Australian Cyber Security Center and is investigating the full extent of the breach and its potential data impact, the filing added.

$ASX:ALQ
Asia

Dexus Secures JV With Boral for Major Ravenhall Logistics Precinct in Melbourne

Dexus (ASX:DXS) has entered a joint venture (JV) with Boral (ASX:BLD) to develop a large-scale logistics precinct in Ravenhall, Melbourne's western corridor, spanning 630 hectares and targeting up to 2.5 million square meters of lettable space, subject to rezoning and regulatory approvals, according to a Tuesday Australian bourse filing.The JV structure gives the company and other capital partners a combined 50% stake, while Boral retains the remaining 50%, with the project developed in staged superlots and supported by substantial third-party capital to enhance capital efficiency, per the filing.The company will oversee rezoning, development, and management, with limited short-term financial impact, while management fees will begin as each stage of investment is completed, the filing added.

$ASX:BLD$ASX:DXS